Actym Therapeutics has filed a notice of an exempt offering of securities to raise $59,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Actym Therapeutics is raising $59,500,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Christopher Thanos played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Actym Therapeutics
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies. Actym is committed to overcoming the hostile tumor immune microenvironment (TME) to bring durable benefits to cancer patients. Our new drug modality is designed to target and enrich in the TME to deliver potent, synergistic payloads in a tumor-specific manner. Our platform is adaptable, with the ability to utilize a variety of payload combinations and has the potential to treat various cancer types.
To learn more about Actym Therapeutics, visit http://www.actymthera.com/
Contact:
Christopher Thanos, Chief Executive Officer
510-256-7167
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.